Bill Text: IL HB2309 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.

Spectrum: Partisan Bill (Democrat 9-0)

Status: (Introduced) 2023-04-06 - Added Co-Sponsor Rep. Michelle Mussman [HB2309 Detail]

Download: Illinois-2023-HB2309-Introduced.html

---

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB2309 Introduced , by Rep. Lindsey LaPointe SYNOPSIS AS INTRODUCED:
305 ILCS 65/15 new
Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.
LRB103 25361 KTG 51706 b
A BILL FOR
HB2309 LRB103 25361 KTG 51706 b
AN ACT concerning public aid.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Early Mental Health and Addictions
Treatment Act is amended by adding Section 15 as follows:
(305 ILCS 65/15 new)
Sec. 15. Pilot program for 8-milligram naloxone nasal
spray kits.
(a) Findings. The General Assembly finds the following:
(1) In its May 2022 Statewide Semiannual Opioid
Report, the Department of Public Health reported that
3,013 fatalities occurred in 2021 due to opioid overdoses.
(2) These 3,013 opioid overdose deaths in Illinois
represent a 2.3% increase from 2020 and a 35.8% spike from
2019.
(3) In 2021, toxicology testing found that 2,672 or
89% of the opioid fatalities involved a synthetic opioid
such as fentanyl.
(4) A 4-milligram naloxone nasal spray has been the
principal tool for bystanders and emergency medical
service providers to revive an individual from an overdose
episode.
(5) A study published in the Harm Reduction Journal in

HB2309 - 2 - LRB103 25361 KTG 51706 b
May 2022 surveyed 125 adult residents of the United States
who were administered a 4-milligram naloxone nasal spray
during an opioid overdose. The study found that 78% of the
adults surveyed reported using at least 2 or more doses of
the 4-milligram naloxone nasal spray. While 30% of the
adults surveyed reported using at least 3 or more doses of
the 4-milligram naloxone nasal spray.
(6) A 2021 article published in the Harm Reduction
Journal reported on a study conducted by the Johns Hopkins
Bloomberg School of Public Health which surveyed 171
people living in suburban Maryland who use opioids.
Sixty-one or 35.7% of the persons surveyed reported having
received take-home naloxone during the 6-month period
immediately prior to the start of the study. 57% of those
persons reported using it to reverse an overdose. Out of
that group of persons who had an overdose reversal, 79%
reported needing at least 2 or more doses of the take-home
naloxone.
(7) The National Library of Medicine recently
published a study that analyzed emergency medical services
(EMS) data collected and stored in the National Emergency
Medical Services Information System database. The study
examined data collected from over 10,000 EMS agencies
across 47 states concerning 946,000 EMS calls that
involved the administration of naloxone. The study found
that naloxone multi-dosing by emergency medical service

HB2309 - 3 - LRB103 25361 KTG 51706 b
providers increased 54% over 5 years, from 18.4% to 28.4%
in 2020.
(8) On April 30, 2021, the U.S. Food and Drug
Administration approved a higher 8-milligram dose naloxone
nasal spray product to treat opioid overdose.
(9) Thirty-three states have Naloxone Standing Orders
that authorize eligible entities to have open access to
the 8-milligram naloxone nasal spray. Those states are:
Ohio, Kentucky, Iowa, Pennsylvania, Massachusetts, New
Jersey, Virginia, Alabama, Florida, Tennessee, Colorado,
Alaska, New Hampshire, Illinois, Arizona, Kansas,
California, Texas, Georgia, South Carolina, North
Carolina, West Virginia, Michigan, Connecticut, Oklahoma,
Minnesota, Maine, Louisiana, Nevada, Idaho, Oregon,
Nebraska, and Vermont.
(10) Thirteen state government agencies have purchased
the 8-milligram naloxone nasal spray: Alabama, Alaska,
Colorado, Florida, Idaho, Iowa, Kentucky, New Hampshire,
Ohio, Pennsylvania, Tennessee, Wisconsin, and West
Virginia.
(11) In November 2021, the U.S. Department of Veterans
Affairs added the 8-milligram naloxone nasal spray to the
VA National Formulary.
(12) 70% of Americans with private health insurance
can access the 8-milligram naloxone nasal spray.
(13) 90% of Americans with Medicaid, including

HB2309 - 4 - LRB103 25361 KTG 51706 b
Medicaid recipients residing in Illinois, can access the
8-milligram naloxone nasal spray.
(14) The current cost of the 4-milligram naloxone
nasal spray is $5.93 per milligram. In contrast, the
8-milligram naloxone nasal spray costs 36.7% less at $3.75
per milligram.
(b) The Department of Human Services shall implement a
2-year pilot program to provide FDA-approved 8-milligram
naloxone nasal spray kits to licensed community substance use
providers and public health departments in Cook County, DuPage
County, Winnebago County, Sangamon County, and St. Clair
County.
The Department of Human Services shall implement a data
collection program to determine the number of 8-milligram
naloxone nasal spray kits administered by emergency medical
service providers and bystanders per overdose incident during
the 2-year term of the pilot program. The data collected must
also include the number of individuals who survived an opioid
overdose after receiving the 8-milligram naloxone nasal spray
and the number of individuals who died of an opioid overdose
after receiving the 8-milligram naloxone nasal spray.
The Department of Human Services shall prepare a report on
the results of the 2-year pilot program and submit the report
to the General Assembly by July 1, 2026.
Section 99. Effective date. This Act takes effect January
1, 2024.